Synergy of Interferon-α and 5-Fluorouracil in Human Renal Cell Carcinoma Requires p53 Activity

European Urology

Volumn 52, Issue 4, 2007, Pages 1131-1139

  Shang, Donghao ^a   Ito, Noriyuki ^a   Watanabe, Jun ^a   Awakura, Yasuo ^a   Nishiyama, Hiroyuki ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Interferon ; p53; Renal cell carcinoma; Synergy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PROTEIN P53; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; KIDNEY CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; MUTATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548227934     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.045     Document Type: Article

References (29)

1. Janzen N.K., Kim H.L., Figlin R.A., and Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
2. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
3. Hartmann J.T., and Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 19 (1999) 1541-1543
4. Atzpodien J., Lopez H.E., and Kirchner H. Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13 (1995) 497-501
5. Lissoni P., Barni S., Ardizzoia A., et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-α. Eur J Cancer 28 (1992) 92-96
6. Hernberg M., Pyrhonen S., and Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 22 (1999) 145-154
7. Dutcher J.P., Logan T., Gordon M., et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 6 (2000) 3442-3450
8. Yanai Y., Horie S., Yamamoto K., et al. Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 21 (2001) 1129-1136
9. Homma Y., and Aso Y. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol 25 (1994) 164-170
10. Steiner T., Junker U., Henzgen B., Nuske K., Durum S.K., and Schubert J. Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur Urol 39 (2001) 478-483
11. Takaoka A., Hayakawa S., Yanai H., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
12. Berenbaum M.C. A method for testing for synergy with any number of agents. J Infect Dis 137 (1978) 122-130
13. Bex A., Kerst M., Mallo H., Meinhardt W., Horenblas S., and de Gast G.C. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 49 (2006) 76-81
14. Verra N., de Jong D., Bex A., et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 48 (2005) 527-533
15. Chawla-Sarkar M., Leaman D.W., and Borden E.C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7 (2001) 1821-1831
16. Ossina N.K., Cannas A., Powers V.C., et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 272 (1997) 16351-16357
17. Thyrell L., Erickson S., Zhivotovsky B., et al. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 21 (2002) 1251-1262
18. Pagliaro L.C., Keyhani A., Liu B., Perrotte P., Wilson D., and Dinney C.P. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 21 (2003) 456-462
19. Liu Q., Hilsenbeck S., and Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 (2003) 4078-4087
20. Mohiuddin M., Chendil D., Dey S., et al. Influence of p53 status on radiation and 5-fluorouracil synergy in pancreatic cancer cells. Anticancer Res 22 (2002) 825-830
21. Wittnebel S., Jalil A., Thiery J., et al. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Network 16 (2005) 123-127
22. Shvarts O., Seligson D., Lam J., et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173 (2005) 725-728
23. Imai Y., Strohmeyer T.G., Fleischhacker M., Slamon D.J., and Koezer H.P. p53 mutations and MDM-2 amplification in renal cancers. Mod Pathol 7 (1994) 766-770
24. Uchida T., Wada C., Wang C., Egawa S., Ohtani H., and Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-Ras, and p53 genes in renal cell carcinomas. Cancer Res 54 (1994) 3682-3685
25. Torigoe S., Shuin T., Kubota Y., Horikoshi T., Danenberg K., and Danenberg P.V. p53 gene mutation in primary human renal cell carcinoma. Oncol Res 4 (1992) 467-472
26. Uhlman D.L., Nguyen P.L., Manivel J.C., et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86 (1994) 1470-1475
27. Contractor H., Zariwala M., Bugert P., Zeisler J., and Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 181 (1997) 136-139
28. Oda H., Nakatsuru Y., and Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 55 (1995) 658-662
29. Zigeuner R., Ratschek M., Rehak P., Schips L., and Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63 (2004) 651-655